PsychonautWiki Archive

25I-NBOMe: Difference between revisions

← Older edit
>Jkadosh15
Added a common cognitive effect of Hallucinogen Persisting Perception Disorder (HPPD) that is commonly caused by psychedelics with stimulant properties like the substituted phenethylamines
>JohntheCaptain
mNo edit summary
 
(21 intermediate revisions by 6 users not shown)
Line 18: Line 18:
==Pharmacology==
==Pharmacology==
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as an unusually potent and selective [[Agonist#Agonists|partial agonist]].<ref name="Ettrup2011" /> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a Full [[Agonist#Agonists|agonist]].<ref name="Ettrup2011" /> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.


Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5-HT2a receptor.<ref name="Ettrup2011" /> Contrary to popular belief, it is not a "full agonist"{{citation needed}}, although questions have been raised about how the effects it produces differ from other 5-HT2a partial agonists, which include the range of traditional psychedelics.
Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5-HT2a receptor.<ref name="Ettrup2011" /> Contrary to popular belief, it is not a "full agonist"{{citation needed}}, although questions have been raised about how the effects it produces differ from other 5-HT2a partial agonists, which include the range of traditional psychedelics.
Line 80: Line 80:
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Headaches]]'''
*'''[[Effect::Headaches]]'''
*'''[[Effect::Seizures]]'''
*'''[[Effect::Seizures]]'''- This effect is far more common in doses exceeding a heavy dose and may manifest as status epilepticus wherein seizures last more than 5 minutes or do not stop without medical intervention
*'''[[Effect::Rhabdomyolysis]]'''


}}
}}
Line 150: Line 151:
*'''[[Effect::Time distortion]]'''
*'''[[Effect::Time distortion]]'''
*'''[[Effect::Wakefulness]]'''
*'''[[Effect::Wakefulness]]'''
*'''[[Effect::Hallucinogen Persisting Perception Disorder]]'''
*'''[[Effect::HPPD]]'''


}}
}}
Line 215: Line 216:
In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.<ref>{{cite web|url=https://op.europa.eu/o/opportal-service/download-handler?identifier=025bb164-4937-11e4-a0cb-01aa75ed71a1&format=pdfa1a&language=en&productionSystem=cellar&part=|title=Council Implementing Decision on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures|date=September 25, 2014|publication-date=October 1, 2014|work=Official Journal of the European Union|pages=22-26|id=L 287|publisher=Office for Official Publications of the European Communites|oclc=52224955}}</ref>
In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.<ref>{{cite web|url=https://op.europa.eu/o/opportal-service/download-handler?identifier=025bb164-4937-11e4-a0cb-01aa75ed71a1&format=pdfa1a&language=en&productionSystem=cellar&part=|title=Council Implementing Decision on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures|date=September 25, 2014|publication-date=October 1, 2014|work=Official Journal of the European Union|pages=22-26|id=L 287|publisher=Office for Official Publications of the European Communites|oclc=52224955}}</ref>


*'''Australia''': Possession, production and sale is illegal.{{citation needed}}
*'''Australia''': Possession, production and sale is illegal.<ref>https://web.archive.org/web/20160602092257/https://www.legislation.gov.au/Details/F2015L01534/Html/Text#_Toc420496379</ref>
*'''Austria''': Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref>
*'''Austria''': Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref>
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
Line 228: Line 229:
*'''Japan''': 25I-NBOMe is a narcotic drug in Japan effective November 1st, 2015.<ref>{{Citation | title=新たに４物質を麻薬に指定し、規制の強化を図ります ｜報道発表資料｜厚生労働省 | publisher=厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)] | url=https://www.mhlw.go.jp/stf/houdou/0000098723.html}}</ref>
*'''Japan''': 25I-NBOMe is a narcotic drug in Japan effective November 1st, 2015.<ref>{{Citation | title=新たに４物質を麻薬に指定し、規制の強化を図ります ｜報道発表資料｜厚生労働省 | publisher=厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)] | url=https://www.mhlw.go.jp/stf/houdou/0000098723.html}}</ref>
*'''Latvia''': 25I-NBOMe is a Schedule I controlled substance.<ref>{{Citation | title=Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | url=https://likumi.lv/doc.php?id=121086}}</ref>
*'''Latvia''': 25I-NBOMe is a Schedule I controlled substance.<ref>{{Citation | title=Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | url=https://likumi.lv/doc.php?id=121086}}</ref>
*'''The Netherlands:''' 25I-NBOMe is classified as a Lijst 1 (List 1) controlled substance under the Opiumwet (Opium Law). <ref>https://wetten.overheid.nl/BWBR0001941/2024-04-16#BijlageI</ref>
*'''New Zealand''': 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>{{Citation | title=Misuse of Drugs Act 1975 No 116 (as at 07 December 2021), Public Act – New Zealand Legislation | url=https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html}}</ref>
*'''New Zealand''': 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>{{Citation | title=Misuse of Drugs Act 1975 No 116 (as at 07 December 2021), Public Act – New Zealand Legislation | url=https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html}}</ref>
*'''Norway''': 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.<ref name="EMCDDA"></ref>
*'''Norway''': 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.<ref name="EMCDDA"></ref>
Line 254: Line 256:
*[https://erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml 25I-NBOMe (Erowid Vault)]
*[https://erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml 25I-NBOMe (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=5380 25I-NBOMe (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=5380 25I-NBOMe (Isomer Design)]
*[https://drugs-forum.com/wiki/25I-NBOMe 25I-NBOMe (Drugs-Forum)]


===Discussion===
===Discussion===
Retrieved from "https://psy.st/wiki/25I-NBOMe"